Péptidos Colombia
ESEN

Retatrutide in Colombia: identity, regulatory status and presentations

Retatrutide is a molecule under development by Eli Lilly and Company, which describes it as an investigational agonist of the GIP, GLP-1 and glucagon receptors. In the query of October 7, 2026, Invima's Unique Drug Code (CUM) registry contained no sanitary registration for retatrutide. This catalog offers it exclusively for research. The article gathers sourced facts on its identity and regulatory status, refers to the product page for presentations and storage, and does not substitute for the buyer's own document review.

What retatrutide is

Retatrutide is a molecule under development by Eli Lilly and Company. On its frequently asked questions page, consulted on October 7, 2026, Lilly describes it as an investigational triple hormone receptor agonist that activates the receptors for GIP, GLP-1 and glucagon. That is the manufacturer's receptor-level description, and this article goes no further than that classification.

In this catalog, Retatrutide is classified as a synthetic triple agonist of the GLP-1, GIP and glucagon receptors and is listed as a reference intended exclusively for research.

Regulatory status in Colombia: sourced facts

Invima publishes the Unique Drug Code (CUM) on datos.gov.co in four datasets: current registrations, expired registrations, registrations in other statuses and registrations undergoing renewal. In the query of October 7, 2026, none of the four contained a sanitary registration with retatrutide as active ingredient or in the product name. The renewal dataset covers renewals, not new applications, so this query does not support any statement about pending applications.

In June 2026, Invima issued three health alerts, each originating from a complaint, that include products offered under the name retatrutide or close spellings of it. By the date of their PDF documents, No. 180-2026 and No. 181-2026 are from June 23, 2026, and No. 184-2026 is from June 24, 2026. Alert 180 spells the names "RETRATUTIDA" and "RETATUTRIDE"; alert 181 uses "Retatrutide", and alert 184 uses "Retatrutida" and "Retatrutide".

According to the text of the three alerts, the products named are not covered by any sanitary registration issued by the competent authority, their marketing in Colombia is illegal and they are considered fraudulent products; as the rule breached, they cite Decreto 677 de 1995. The alerts add that, because they do not comply with that regulation, the products have not been evaluated for quality, safety or efficacy. They advise the general public to refrain from acquiring them. Each alert also includes a section for holder establishments, distributors and marketers, which tells them to refrain from distributing and marketing those products, because marketing them may lead to sanitary safety measures.

On the development status, Lilly states on the same page that retatrutide is in Phase 3 clinical trials and that its launch depends on completing them and on the regulatory approval process. These are the manufacturer's statements, consulted on October 7, 2026.

The references in this catalog are not medicines and have no Invima sanitary registration for use in humans or animals, according to the site's sanitary notice (/en/legal/sanitary-notice). The article “What "research grade" means for a peptide” explains why that label is not a sanitary registration, and “Importing research peptide supplies into Colombia” describes the difference between importing a supply and importing a drug.

Presentations and reference prices

The presentations, reference prices and availability of Retatrutide are on its catalog product page.

Storage

The storage conditions declared by the catalog are covered in the article "Storage and transport of research peptides". This article does not repeat them: the current value is the one shown in the technical block of the Retatrutide product page.

Frequently asked questions

What is retatrutide?
It is a molecule under development by Eli Lilly and Company, which describes it as an investigational agonist of the GIP, GLP-1 and glucagon receptors. This catalog lists it as Retatrutide and offers it exclusively for research.
Does retatrutide have an Invima sanitary registration?
In the query of October 7, 2026, none of the four Unique Drug Code (CUM) datasets contained a retatrutide registration. The references in this catalog have no sanitary registration for use in humans or animals, according to the site's sanitary notice.
Where can the presentations and reference prices be found?
The presentations, reference prices and availability of Retatrutide are on its catalog product page.
Does this article teach reconstitution or how to apply the material?
No. This site does not publish reconstitution steps or routes of administration. The reference is offered exclusively for research.

Sources

Related catalog references

Catalogued references from the families this document covers. Each sheet states presentations, current public price, and what batch documentation can be requested.

  • Retatrutidesynthetic triple agonist of the GLP-1, GIP and glucagon receptors · Metabolic research peptides
  • Tirzepatidesynthetic dual agonist of the GLP-1 and GIP receptors · Metabolic research peptides
  • 5-amino-1mqsmall molecule that inhibits the NNMT enzyme · Metabolic research peptides
  • Adipotidepeptidomimetic with a prohibitin-binding domain · Metabolic research peptides
  • AOD9604modified 176-191 fragment of somatropin · Metabolic research peptides

Keep browsing the catalog

Last reviewed: 2026-10-07. This site presents a technical catalog of references intended exclusively for research, technical or laboratory purposes. The published information is not medical advice, a prescription or a diagnosis, and the references are not for human or veterinary use. The availability, import, sale and dispatch of any reference are subject to document validation and to the health, customs and regulatory rules that apply in Colombia and in the destination country.